Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 89 | Code: MRS - 18541


Global Markets Directs, Complicated Skin And Skin Structure Infections (cSSSI) Pipeline Review, H2 2014, provides an overview of the Complicated Skin And Skin Structure Infections (cSSSI)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Complicated Skin And Skin Structure Infections (cSSSI)
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Complicated Skin And Skin Structure Infections (cSSSI) and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Complicated Skin And Skin Structure Infections (cSSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Complicated Skin And Skin Structure Infections (cSSSI) pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Complicated Skin And Skin Structure Infections (cSSSI)
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Complicated Skin And Skin Structure Infections (cSSSI) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content 

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Complicated Skin And Skin Structure Infections (cSSSI) Overview 8
Therapeutics Development 9
Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI) - Overview 9
Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI) - Comparative Analysis 10
Complicated Skin And Skin Structure Infections (cSSSI) - Therapeutics under Development by Companies 11
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Complicated Skin And Skin Structure Infections (cSSSI) - Products under Development by Companies 16
Complicated Skin And Skin Structure Infections (cSSSI) - Companies Involved in Therapeutics Development 17
Cempra, Inc. 17
CrystalGenomics, Inc. 18
Debiopharm International S.A. 19
Dong-A Socio Group 20
Furiex Pharmaceuticals, Inc. 21
GlaxoSmithKline plc 22
Melinta Therapeutics, Inc 23
Microbion Corporation 24
Paratek Pharmaceuticals, Inc. 25
The Medicines Company 26
Complicated Skin And Skin Structure Infections (cSSSI) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 35
acorafloxacin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Bismuth ethanedithiol - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CG-400549 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Debio-1450 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Debio-1452 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
delafloxacin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
fusidic acid - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
GSK-2140944 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
lanopepden - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
omadacycline - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
oritavancin diphosphate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
tedizolid phosphate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Complicated Skin And Skin Structure Infections (cSSSI) - Recent Pipeline Updates 63
Complicated Skin And Skin Structure Infections (cSSSI) - Dormant Projects 82
Complicated Skin And Skin Structure Infections (cSSSI) - Discontinued Products 83
Complicated Skin And Skin Structure Infections (cSSSI) - Product Development Milestones 84
Featured News & Press Releases 84
Apr 30, 2014: Cubist to Present New Pipeline Data Of Tedizolid Phosphate At 2014 European Congress of Clinical Microbiology and Infectious Diseases 84
Feb 27, 2014: European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Oritavancin 84
Oct 22, 2013: Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections 85
Sep 04, 2013: Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug 86

Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 89
Disclaimer 89

List of Tables

Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI), H2 2014 9
Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Cempra, Inc., H2 2014 17
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by CrystalGenomics, Inc., H2 2014 18
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Debiopharm International S.A., H2 2014 19
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Dong-A Socio Group, H2 2014 20
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Furiex Pharmaceuticals, Inc., H2 2014 21
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by GlaxoSmithKline plc, H2 2014 22
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Melinta Therapeutics, Inc, H2 2014 23
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Microbion Corporation, H2 2014 24
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 25
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by The Medicines Company, H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 34
Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics - Recent Pipeline Updates, H2 2014 63
Complicated Skin And Skin Structure Infections (cSSSI) - Dormant Projects, H2 2014 82
Complicated Skin And Skin Structure Infections (cSSSI) - Discontinued Products, H2 2014 83

List of Figures

Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI), H2 2014 9
Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Products, H2 2014 15
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Top 10 Targets, H2 2014 28
Number of Products by Stage and Top 10 Targets, H2 2014 28
Number of Products by Top 10 Mechanism of Actions, H2 2014 30
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 30
Number of Products by Top 10 Routes of Administration, H2 2014 32
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 32
Number of Products by Stage and Top 10 Molecule Types, H2 2014 34

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing